SCHEMBL565739

SCHEMBL565739

CC(C)CN(Cc1cc(Cl)c2c(c1)OCCCC2)C(=O)C(C)CNCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 5/20 0.55
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
RECQL P46063 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TSHR P16473 3/20 0.35
USP2 O75604 1/20 0.35
BACE1 P56817 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
BACE2 Q9Y5Z0 1/20 0.33
BDKRB1 P46663 1/20 0.33
DRD2 P14416 3/20 0.33
DRD4 P21917 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15693909 0.88 PROKR2 (0.69) PROKR2ALDH1A1SMN1; SMN2HPGDKDM4E
SCHEMBL565524 0.88 PROKR2 (0.69) PROKR2ALDH1A1SMN1; SMN2HPGDKDM4E
SCHEMBL565109 0.88 PROKR2 (0.69) PROKR2ALDH1A1SMN1; SMN2HPGDKDM4E
SCHEMBL565087 0.87 PROKR2 (0.65) PROKR2ALDH1A1SMN1; SMN2HPGDMEN1
SCHEMBL10107414 0.86 PROKR2 (0.55) PROKR2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL565257 0.86 PROKR2 (0.53) PROKR2ALDH1A1SMN1; SMN2HPGDKDM4E
SCHEMBL565533 0.84 PROKR2 (0.56) PROKR2ALDH1A1SMN1; SMN2HPGDKDM4E
SCHEMBL565336 0.84 PROKR2 (0.62) PROKR2KMT2ANPC1
SCHEMBL565861 0.84 PROKR2 (0.59) PROKR2
SCHEMBL564098 0.82 PROKR2 (0.57) PROKR2ALDH1A1SMN1; SMN2HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof PROKR2, PROKR1, GIPR PROKR2 1/4885ALDH1A1 4725/4885SMN1; SMN2 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.